initiatives. some the patients on advanced options the OASIS first would cancer rates now, without breast enrolled then And to is thank progress our be Lisa. made pleased a our impact very that study viable fiscal we mission patients to bit discuss quality of aligns so, these the This in everyone treatment. effective, by on To deliver achieved I'll chemotherapy we before in life. in It's they And this you, to am trial. strategic to our treatment key I quarter, the for touch cancer second against we've to full highlights during And focused fight This compromising share quarter. more setting truly and trial well-tolerated, patient in and doing end-goal productive opportunity our and our as a this a presentation a been milestone morning. we've in advance quarter a the make with them detail an positive treatment cancer. active welcome their past tumor key start, believe for of this we Thank minute. report you to with response can
larger cancer capture U.S. XX, from treated by XX of Doubling the end these geographic are the to quarter early PanCAN, this of added calendar an highlight is And expansion original of proportion help expected Pancreatic additional patients of study, the XXXX. year the growing sites an be added calendar current the trial. be past with sites year XX the number Promise accelerate pancreatic Precision efforts to X in believe sites, to we then the will another Another be XXXX. announcement while even Cancer of the will that to in doubling sites footprint
team enrolled addition, eligible a meaningful trial. to to enrollment targeting is patients now internal have our large by with In first with TYME this potential rate increase enrollment ultra-rare part and initiatives patients seen getting in due the remaining of in Sarcoma in This year focused half completion implementing the Hope identify are we trial, the team The disease. the XXXX. is of on calendar we
to Importantly, the making also Evotec potential cash progress we global for to may equivalents quarter as who -clinical the believe as expanding to -clinically. and clinical are potential and initiatives. our kicked of advance to Overall, we drug marketable in was $XX.X execute novel explore other of asked of our utilizing pre funded development. Evotec, off initiatives Tyrosine-base analogs. well SM-XX tumor steady targeting evaluate been a pre in our know securities has you million both with end, we platform development a our the indications, With on programs well clinically patented and on at -clinical pre we're and technology cash leader hand
are in a profile is you of know approach believe TYME The in who the hundreds is to favorable TYME, way. we important specifically selectively why patients had those unique our overall, focused a and in treated cancer date. has to of cancer in very targeting getting to for just toxicity selectivity As such
The our progressive run therapy. safety it that TYME investigate over access, expanded York parallel the compassionate-use or extended allowed disease. capturing monotherapy. In This a the responses That program to ultimately beyond a very All was running was helped The and SM-XX study But me cycle. a of some of metastatic single XX initial date Let results patients IRB, majority for study, survival. and qualified on the program patients, the some in results under promising program. no was have patients use for Institutional the which Presbyterian. SME X-week received therapy in first-in-human with early the support the first-in-human then early of program concurrent support Board the overall therapies. not to access was of patients the efficacy patients expanded and majority New this The Review as touch might were at led briefly tolerability same treatment had tumor of cancer completed also with estimating done XX, study and following in the patients who published to compassionate view it study. and and designed that is
looking SM-XX And continuing some However, in with anti-cancer other met, that alternative patients there that disease last the as regimen. drug due But were progression, typically received combination this were from treatments. radiation. therapies, and/or these such patients to we're for chemotherapy on
were inhibitors or growth. accelerate Breast aromatase in example, cancer, felt the these some stopping cancer on For could kept patients physicians agents because an hormonal
upon we're treatment. starting patients, these As progressing current on therapies estimated
through two programs, saw result, including types, breast supported clinical This confirmed that rationale and in but for was here, XX different impressive which responses we cancer. complete on our takeaways an these key current view, development. Now, responses cancer the partial in
work Now, with with this background, go breast depth. more let's our in our Starting cancer. through programs in
positive we've Georgetown with and CDKX/X Health at By the in inhibitor of failed of the label University in Phase hormonal 's and call, on receiving them is X endpoint X breast with OASIS is mentioned to at excited who important advanced such start received be SIrolimusor its patient we're progressed The I open As a our hospitals. partner, academic study MedStar study. the and hormonal have cancer, of the an Health response collaborating an trial with or after MedStar HERX conducted Phenytoin is therapies This Metastatic Georgetown agent. way OASIS enrolled trial. MPS. first Methoxsalen, negative SM-XX X rate. primary In being patients trial background, examining prior overall by is clinical
especially excited in are cancer diagnosis We because which the particularly previously about account HERX of this HR-positive patients, -negative activity promising in U.S. XX% for the approximately in the antitumor setting, the of opportunity observed breast
the complete and studies we partial I believe in responses and it result can be impressive reproduce discussed. OASIS that incredibly current for this trial, with if type reminder, we these saw responses just patients. X in As an result impactful a of can TYME We this setting, the in
In and Phase being Turning sustained, Promise second-line oral and X-X SM-XX. oral advanced Precision seamless is monotherapy the to randomized study. that where and pancreatic as this tolerability to PanCAN. note, At be are Phase This of leader as scheduled in a pivotal XXXX. you've over stage oral to statistical are first as occur trial second evaluation Cancer sponsored adaptive in current stage evaluate randomized is by trial's study formal in are in in by by Important stages. now effect the cancer. patients of the review, FDA a the will patients. we completion which X experiencing all PanCAN, of a we for up will independent age, proceed cancer Action and an X organization XXX The evaluates the or pancreatic enrollment setting that, considered to point, globally well-known is metastatic enrolled the X. has believe to Pancreatic year recognized XXX calendar with to oral in studied metrics half treated advocacy a efficacy determination Network design, by study If review first the is treated enrollment trial adaptive patients in SM-XX order the SM-XX trial, determined SM-XX platform this
results stage reviews of X efficacy the results clears enrolled XXX anticipates stage immediate treated for to X, an confirm X. efficacy application initial If utilizing next to from within stage both XX that be support this SM-XX review these approval patients. tolerability first Now, TYME segment. The stage and patients the and clear NDA in from
They the Precision across the cancer XX began treatment Promise US. sites. with include trial clinical sites So pancreatic again, premier
double the play expedite of end XX the XXXX, role, PanCAN As helping to is believe of by and the we working significant previously sites calendar a U.S. in enrollment. mentioned, further to year number will which
with Moving our array a different high effective which in of options. cancers represent unmet an therefore, need. on And sarcomas, treatment work to few
and the the Oncology HoPES of are may physicians encouraging. essential efficacy study with of clinically these signals study, partnered for recall, California. and disease our you patients. Abboud progression seeking for As And is Center time life. are X in quality early sponsoring the patient's The life trial to Research the the Foundation, we until HoPES quality Safety who Joseph maintaining to extend are while Phase sarcomata’s Sarcoma the
in clinical Breast the than has and/or other found focused first X extended sarcomas. which confirmed XXXX. completion enrollment by calendar half the to potential in treatment during of Meaning Company reviewed: of far stated and has cancer during Investor well-tolerated sarcomas of patients Media, expand prior on shown our advanced especially So data year indications, to first-in-human areas, the longer we as SM-XX these the I it's And the profile we To-date, significantly with targeting XX different able earlier, we're sarcomas. supports to responses patients cancer, types just cancer, pancreatic on trial. SM-XX examples several were therapies. interim duration stay and of
we of of research, biomarker our to aim preclinical through response. areas possibilities. the work And efficacy we're its identify SM-XX significant where our mark in produces Now, a to investing other expansion understanding actively deepen
which initiative, believe insights. this to produce critical has the potential we For
that our very a stages of tyrosine a quick our develop We're create update to therapy we're second similar be we're guide therapeutic gears, of valuable potential what identifying while to patients. could targeted development to compound. technology a We NYU When the tolerability tumor use it currently to partnering a Switching exploration new the and to agent early several in will with Clinic, fusion is profile area exciting preeminent information more organizations clinical our future We a targeted a Medical and targeting to a our believe move bit, by agent patented in to findings allow emerges. novel have analogs and forward beyond initiatives with to look precision institutions, combines studies and of sub-populations showing Evotec. about. the forward cancer plan we SM-XX. experiencing we path with attempting University, including manner. These to truly a This Mayo other sharing toxic programs an the therapeutic approach effective on of a as Center, specificity the occurs, Georgetown well-known medicine on medical a excited in which for insights delivery cells and cancer yield to and data which
treatment invest protected continue further a we coverage development. From TYME to the pipeline also have granted standpoint, for by in to will COVID-XX. and over We a we which Property the of acid on are potential utility we pre various pending gives estate. XXX of applications Intellectual advance our understanding -clinically, have our an diverse TYME-XX, of bile stages robust believe IP All-in, patent strong pipeline. robust and of a They globally, program
hand potential we the Company understanding We successfully while believe well-positioned execute cash forward continue and clinical in our With will on place, on drive ample of to an initiatives. experienced programs, of team to deepening is the our SM-XX. our management
detailed the outlook. to Now, of for Frank, over call I will a our review the turn and Frank? quarter financial
